Royalty Pharma is heading into the second half of August with a quietly unusual setup — options positioning has swung to its most bullish extreme of the past year, even as the stock puts in a steady 3.2% week and the broader pharma sector stumbles.
The clearest signal is in options. The put/call ratio collapsed to 0.14 on August 14, nearly 3.6 standard deviations below its 20-day average of 0.21 — the lowest reading in a year, against a 52-week range of 0.09 to 1.44. That is not a modest lean toward calls; it is a crowded tilt. For most of the past six weeks, the PCR had been holding steadily around 0.21 with very little volatility. The break lower arrived abruptly, which makes it worth monitoring whether this reflects a genuine conviction trade or expiry-driven positioning noise.
Short interest tells a much quieter story, and is arguably the least interesting data point on the sheet right now. Bears covered hard last week — short interest fell roughly 11% in seven days to 2.5% of the free float, one of the sharper weekly reductions in the 30-day window. Before that move, shorts had been parked near 12.5 million shares through most of July; they now sit below 10.8 million. Borrow conditions offer no drama whatsoever: cost to borrow is barely 0.50%, and availability is extraordinarily loose at over 4,000% — meaning for every share currently lent out, there are roughly forty more available to borrow. There is no squeeze dynamic here, and the short score of 34 sits comfortably in the low-pressure zone.
The Street has been directionally constructive on RPRX for some time, and the most recent action reinforces that. JP Morgan's Chris Schott lifted his price target to $62 from $58 on August 7, the day after the latest earnings print, maintaining Overweight. That move is fresh and relevant — it puts the JP Morgan target above the current $58.60 close and implies modest but positive upside. TD Cowen and Citigroup had both raised targets more aggressively earlier in the summer, with TD Cowen going to $65 and Citi to $66. The consensus sits at Hold with only a single hold on record, which likely understates the overall bullish lean given the volume of Buy-rated target raises. Valuation multiples have drifted but remain undemanding: EV/EBITDA has compressed about half a turn over 30 days to 10.9x, while the P/E of 10.5x has been essentially flat. Forward EPS momentum is strong — the 12-month forward earnings growth factor ranks in the 94th percentile of the universe — even as the EPS surprise factor scores a modest 9, suggesting the company beats less often than it grows.
On the institutional side, the picture is broadly supportive. Capital Research holds 10.7% of shares and added nearly 1.8 million shares in the latest reporting period. BlackRock added 1.9 million, and Norges Bank added close to 2 million. The main counterweight is Mario Giuliani, who trimmed 2.9 million shares in the period to June 12, bringing his position to 4.8% — a notable reduction but still a substantial holding. Founder and CEO Pablo Legorreta reported a modest 209,000-share addition as recently as August 5, the same day the company awarded stock to senior executives including CFO Terrance Coyne. Recent cash sales by insiders — the Executive Vice Chairman sold roughly $7.3 million worth in late June — look like routine compensation monetisation rather than a directional signal, and the 90-day net across all insiders remains positive at $21.6 million.
Against its closest correlated peers, RPRX's 3.2% week looks particularly clean. LLY fell 0.5% on the week, MRK gained 5.6%, and AZN dropped 3.7%. The royalty-stream business model continues to insulate the company from the pipeline and operational volatility hitting conventional drug manufacturers — a point the prior peer note captured well, and one the data continues to support. The next scheduled earnings event is November 6, which is far enough out that near-term catalysts are limited. The key question into autumn is whether the extreme call-heavy options positioning resolves through further price appreciation or simply rolls off — and whether the short covering of the past week marks the end of a positioning adjustment or the beginning of a more sustained reduction in bearish interest.
See the live data behind this article on ORTEX.
Open RPRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
